It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Abstract
An efficient and high yielding process for the production of impurity free rivaroxaban (1), an anti-coagulant agent using alternate synthon is reported. The key components of the process involve; synthesis of 4-(4-aminophenyl)-3-morpholinone (5) using easily available inexpensive nitro aniline (17), condensation of 4-{4-[(5S)-5-(aminomethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl}morpholin-3-one hydrochloride (9) with alternate synthon 4-nitrophenyl 5-chlorothiophene-2-carboxylate (11) in dimethylsulfoxide (DMSO) as a solvent and triethylamine as a base and isolation of the rivaroxaban (1) by designing the crystallization in same reaction pot using specific combination of acetonitrile and methanol as anti-solvents to obtain highly pure rivaroxaban (1) with desired ploymorphic form with an overall yield of around 22% (Calculated from 17). The developed process avoids the use of hazardous chemicals, critical operations and tedious work-ups. Potential impurities arouse during the reaction at various stages and carry-over impurities from starting materials were controlled selectively by designing reaction conditions and tuning the crystallization parameters.
Graphical abstract
[Figure not available: see fulltext.]
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer